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Summary: A monoclonal antibody, designated 2E1, against human pancreatic phospholipase A2 was produced
by hybridization of myeloma cells with spieen cells of immunized BALB/c mice. The hybridomas were screened
for antibody production by time-resolved fluoroirnrnunoassay (TR-FIA). The antibody was found to belong
to subclass I of murine IgG. The specificity of the antibody was confirmed by immunohistochemistry of
pancreatic and other tissues, by immunoblotting of a crude aqueous extract of human pancreas and purified
human pancreatic phospholipase A2 and by TR-FIA. A solid-phase time-resolved fluoroimmunoassay was
developed by using the monoclonal anti-phospholipase A2 antibody äs the catching antibody and a polyclonal
sheep anti-phospholipase A2 antibody labelled with europium äs the detecting antibody. The validity of the
new TR-FIA of human pancreatic phospholipase A2 was confirmed by using it to measure the phospholipase
A2 concentrations in serum samples from healthy subjects and from patients suffering from acute pancreatitis.
Introduction - ..
 A A r ,A. _,other mahgnant tumours of vanous types (4). The
Pancreatic phospholipase A2J) is a digestive enzyme increasedconcentrationofimmunoreactive pancreatic
synthesized by pancreatic acinar cells and secreted äs phospholipase A2 in serum is a sensitive indicator of
an enzymatically inactive proenzyme into the duo- acinar cell damage in acute pancreatitis and other
denum, where it is transformed into an active form pancreatic injuries (5). In patients with liver, gall
by limited hydrolysis by trypsin. Only two immuno- bladder and pancreatic cancer, the elevation of serum
chemicäl techniques for measuring the concentration phospholipase A2 correlated with the stage of the
of pancreatic phospholipase A2 in serum and other disease (4).
body fluids have been developed. These methods are
based on either time-resolved flüoroimmünoassay The purpose of the present study was to prepare
(TR-FIA) (1) or radioirnmunoassay (RIA), (2, 3), and monoclonal antibodies against human pancreatic se-
employ polyclonal änti-phospholipase A2 antibodies cretory phospholipase A2, to test their specificity and
raised in rabbits. Ari RIA-method employing a mono- to devel°P a new immunoassay for the measurement
clonal antibody was described recently (4). Increased of the phospholipase A2 concentration m serum.
values of immunoreactive pancreatic phospholipase Time-resolved fluorescence was used äs a detecting
A2 have been found in sera of patients suffering from method in a solid-phase sandwich assay. The mono-
acute pancreatitis (5, 6), pancreatic qancer (5) and donal antibody was used as the catchinS antibody
and polyclonal anti-phospholipase A2 antibody la-
!) Enzymes· belled with an europium (Eu) chelate was used as the
Phospholipase A2, phosphatide 2-acylhydrolase (EC 3.1.1.4) detecting antibody.
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Materials and Methods
Reagents
Fetal calf serum was purchased from Gibco Laboratories,
Grand Island NY., USA. Hypoxanthine-aminopterin-thymidine
concentrate, Pristane and Freund** adjuvant were from Sigma,
St. Louis MO., USA. Hypoxanthine-thymidine concentrate was
from Flow Laboratories, Irvine, Scotland. KC 2000 medium
was from Hazleton Biologics, St. Lenexa, KS., USA. The eu-
ropium chelate for labelling the anti-phospholipase A2 antibody
was from Wallac, Turku, Finland. Affi-gel Protein A MAPS II
kit was from Bio-Rad Laboratories, Richmond CA., USA and
Serotec Isotyping Kit for monoclonal antibodies from Serotec,
Oxford, England. NS-1 myeloma cell h'ne was obtained from
the Department of Virology, University of Turku, Turku, Fin-
land. Rabbit anti-mouse immunoglobulins were from Dako-
patts, Glostrup, Denmark. Vectastain ABC-kit and ABC-AP-
kit for immunostaining procedures were from Vector Labora-
tories, Burlingame, CA., USA and nitrocellulose from Milli-
pore, Molsheim, France. Activated CH-Sepharose 4B and Seph-
adex G50 were from Pharmacia, Uppsala, Sweden. Trisacryl
GF2000 gel was from IBF, Villeneuve-la-Garenne, France. Mi-
crotitre plates used in TR-FIA measurements were from Eflab,
Helsinki, Finland. Porcine pancreatic phospholipase A2 and bee
venom phospholipase A2 were from Sigma, St. Louis MO.,
USA. Human ascitic phospholipase A2 was purified from cell-
free ascitic fluid from patients suffering from ovarian carcinoma
and peritoneal \carcinosis, äs described earlier (7). Rat pan-
creatic phospholipase A2 was purified by a method described
earlier (8) from pancreases of Wistar rats (Kortesuo, P., Hie-
taranta, A. & Nevalainen, T, to be published).
Solutions and buffers
The TR-FIA assay buffer and the enhancement solution were
from Wallac, Turku, Finland. Tris/saline/azide buffer consisted
of 50 mmol Tris-HCl pH 7.75 containing 9 g of NaCl and 5 g
of NaN3 per litre. Microtitre plates were washed with a solution
containing 9 g of NaCl, 0.2 g of NaN3 and l g of Tween 20 per
litre. The Saturation solution consisted of Tris/saline/azide
buffer containing l g of bovine serum albumin, 60 g of D-
sorbitol, 111 mg CaCl2 (anhydrous) and 39.3 mg diethylene-
triaminepentaacetate (DTPA, Titriplex V) per litre. All chemi-
cals used were of analytical grade.
Standards
Human pancreatic phospholipase A2 stock solution was diluted
with TR-FIA assay buffer to give four Standard concentrations
1.5,9.0, 54and324 g/L
Serum samples
Sera for the determination of the normal reference interval of
immunoreactive pancreatic phospholipase A2 were obtained
from 57 healthy volunteers (23 women and 34 men). The av-
erage age was 41 years (ränge 20—64). Serum samples were
also obtained from 39 patients suffering from acute pancreatitis,
7 women and 32 men, average age 64 years (ränge 52—85) and
42 years (ränge 23-69), respectively. The "diagnosis of acute
pancreatitis was based on clinical presentation (abdominal pain,
nausea, vomiting), radiological (CT-scan) fmdings and elevated
serum and/or urinary amylase concentration, and on operative
findings in 14 patients. The aetiology was biliary disease in 5,
alcohol in 31 and unknown in 3 patients. All sera were stored
at -20 °C until assayed.
Apparatus
Microtitre plates were washed in a 12-well aspirating-washing
device (Wellwash 4) and incubation in an automated shaking
device (Wellmix 3) from Denley, Billingham, England. Fluores-
cence was measured with an Arcus fluorometer, Wallac, Turku,
Finland. Electrophoresis was performed with a PhastSystem™
apparatus, Pharmacia, Uppsala, Sweden.
Purification of human pancreatic phospholipase A2
Phospholipase A2 was purified from .human cadaver pancreas
äs described earlier (8).
Preparation of antibodies to human pancreatic phos^
pholipase A2
Monoclonal antibodies were produced according to the method
of Galfre & Milstein (9). Briefly, male mice (BALB/cKuo, from
the University of Kuopio, Kuopio, Finland) were irnmunized
three tirnes at two-week intervals subcutaneously with 50 g of
purified human pancreatic phospholipase A2. For the first inv
munization, the antigen was mixed with complete Freunds
adjuvant (l -h l by vol.) and for the second and third immu^
nizations with incomplete Freunds adjuvant. After the third
immunization, the animals were bled and tested by TR-FIA
for specific antibody. The animal that showed the highest an-
tibody response against phospholipase A2 at serum dilution
l : 100 was boosted intravenously via the tail vein with 100 g
of antigen in 100 of saline. Three days after the booster
injection, the mouse was killed arid its spieen cells were har-
vested and fused with mouse myeloma cells (NS-1) by treatnaent
with 500 ml/l PEG 4000 in KC 2000-medium containing 200
ml/l fetal calf serum. The fused cells were cultured in hypoxari-
thine-aminopterin-thymidine medium supplemented with 200
ml/l fetal ealf serum until myeloma cells disappeared, after
which they were cultured in hypoxanthine-thymidine medium
supplemented with 200 ml/l fetal calf serum. Hybridoma su-
pernatants were tested for antibody productipn by TR-FIA.
Positive cells were cloned two times by the limiting dilution
method. Finally the resulting hybridömas were injected into the
peritoneal cavity of BALB/c mice pretreated with pristane to
obtain monoclonal antibodies in the ascitic fluid.
Antiserum to human pancreatic phospholipase A2 was raised
in a sheep. The sheep was immunized three times at three-week
intervals subcutaneously with 0.1 mg of purified phospholipase
A2 in Freunds complete adjuvant. Serum was collected two
weeks after the last booster injection.
The immunoglobulin subclass of the monoclonal antibody was
determined in hybridoma supernatants with the Serotec Isotyp-
ing kit for monoclonal antibodies aecording to the manufac-
turer's instructions.
Purificatiori of antibodies
Polyclonal sheep antibodies were purified by passing the anti-
serum through an affinity column containing human pancreatic
phospholipase A2 coupled to CH-Sepharose 4B äs a ligand.
The coupling of protein to the gel was performed according to
the manufacturer's instructions. The specific anti-phospholipaße
A2 antibody was eluted with 7.5 mol/1 sodium thidcyanate in
phosphate buffer (pH 7.3).
The monoclonal antibody was purified by affinity chromato-
graphy with the Protein A MAPS II kit.
Electrophoresis and immunoblotting
The specificity of the monoclonal antibody was determined by
immunoblotting of purified human pancreatic phospholipase
A2 and a crude aqueous extract of human pancreas after am-
monium sulphate precipitation (8). Electrophoresis was per-
formed on SDS-PAGE 8-25% gradient gel with the Phast-
System™ apparatus according to the manufacturer's instruc-
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tions. Proteins were visualizcd by Coomassie blue staining.
Proleins were transferred to nitrocellulose filters with the
PhastSystem semidry immunoblotting device according to the
manufacturer's instructions. The Vectastain ABC-kit was used
for the immunostaining of the nitrocellulose filters.
For the TR-FIA of human pancreatic phospholipase A2 em-
ploying only polyclonal anti-phospholipase A2 antibodies, the
microtitre wells were coated with affinity-purified polyclonal
sheep anti-phospholipase A2 antibody (5 μg/200 μΐ per well) by
physical adsorption overnight. Otherwise the assay procedure
was the same s described above.
Immunohistochemistry
Samples of human pancreas and various other tissues were
from the files of the Department of Pathology, University of
1\irku, Turku, Finland. The tissues were fixed in buffered for-
malin, embedded in paraffin, and sectioned at 5 μπ). The im-
munostaining was performed by using the monoclonal antibody
2E1 s the primary antibody and a Vectastain ABC (avidin-
biotin complex) kit for detecting the site of the immunoreaction
according to the manufacturer's instructions. In control stain-
ings, the primary antibody was replaced by either bovine serum
albumin or a non-related monoclonal antibody (anti-IgE anti-
body).
Labelling of phospholipase A2 an t ibody
The affinity-purified sheep anti-phospholipase A2 antibody was
labelled with an isothiocyanate derivative of the europium
chelate (Eu3+-N'-(p-isothiocyanatobenzyl)-diethylene-triamine-
Nt,N2,N3,N3-tetraacetate) s described earlier (l, 10). The eu-
ropium chelate at 53-fold molar excess was allowed to react
with the affmity purified antibody. The pH was adjusted to 9.5
with l mol/1 Na2CO3 solution. After an overnight incubation
at 4 °C, the labelled antibody was separated from excess reagent
by gel Filtration through a column l .8 cm in diameter and filled
with Trisacryl GF2000 to a height of 37 cm with an additional
9 cm of Sephadex G50 on top. The column was eluted with 50
mmol/1 Tris/saline/azide buffer. About 9 moles of EU were
incorporated per mole of immunoglobulin.
Coating of polystyrene microtitre plates
Microtitre plates made of polystyrene were coated with the
monoclonal anti-phospholipase A2 antibody (25 mg/1) by phys-
ical adsorption from 0.2 ml of Tris/saline/azide buffer overnight.
The plates were washed two times in an automatic washing
device before use.
Time-resolved fluoroimmunoassays
Measurements with TR^FIA were performed s described ear-
lier (1). Serum samples of immunized mice and hybridoma
supernatants were tested in microtitre plates coated with aflin-
ity^purified polyclonal anti-phospholipase A2 antiserum (l μg
cpntained in 100 μΐ added to each well). The coated plates were
washed four times, after which either 5 ng (100 μΐ/well) of
purified pancreatic phospholipase A2 (positive tests) or 100 μΐ
of assay buffer (negative tests) were pipetted intp the wells.
After incubation for l h and washing, 30 μΐ of serum dilution
or hybridoma growth medi m with 70 μΐ assay buffer were
added. Positive cells were detected with 100 ng (100 μΐ/well) of
Eu-labelled rabbit antibodies to mouse IgG.
For the TR-FIA of human pancreatic phospholipase A2, 25 μΐ
of serum sample or human phospholipase A2 Standard in TR-
FIA assay buffer were pipetted into the microtitre wells, which
had been coated with monoclonal anti-phospholipase A2 anti-
body and c ntained 175 μΐ of TR-FIA assay buffer. After l h
incubation with shaking at room temperature, the wells were
aspirated and washed six times, and the Eu-labelled polyclonal
anti-phospholipase A2 antibody (500 ng/well) was added. The
washing Step was repeated after l h and 200 μΐ of enhancement
solution was added. After 5 minutes shaking and 10 minutes
Standing, fluorescence was measured with an Arcus fluorometer.
Statistics
The ninety five per cent reference interval was calculated ac-
cording to the recommendations of the International Federa-
tion of Clinical Chemistry (11). The Refval statistical analysis
System (H. Solberg, Department of Clinical Chemistry, Riks-
hospitalet, Oslo, Norway) Software package was used for the
statistical analysis and calculation of the reference interval on
a microcomputer.
Results
Monoclonal antibody 2E1 against human
pancreatic phospholipase A2
One of the hybridomas, 2E1, produced an antibody
that specifically reacted with human pancreatic phos-
pholipase A2. The purity of the monoclonal antibody
2E1 after the affmity purification with MAPS II Kit
was verified by SDS-PAGE, where it gave homoge-
neous protein bands with relative molecular masses
of approximately 62000 (heavy chain) and 25000
(light chain). The subclass of the monoclonal antibody
2E1 was identified s IgGl.
The specificities of monoclonal and polyclonal anti-
bodies were determined by immunohistochemistry
and immunoblotting. An aqueous extract of human
pancreas and purified pancreatic phospholipase A2
were resolved by SDS-PAGE, blotted to a nitrocel-
lulose membrane and stained with monoclonal and
polyclonal antibodies. The monoclonal antibody 2E1
reacted with one protein band only in both cases. The
antibody 2E1 recognized the non-reduced native form
but not the reduced form of the human pancreatic
phospholipase A2 enzyme (fig. 1). The polyclonal
sheep anti-phospholipase A2 antiserum gave one pro-
tein band with purified human pancreatic phospho-
lipase A2 (fig. 1). It recognized, however, one major
band of apparent MT about 15000 and another weak
band of higher Mr in the aqueous extract of human
pancreas (fig. 1). Phospholipase A2 was found in the
cytoplasm of pancreatic acinar cells by immunohis-
tochemistry using the monoclonal antibody 2E1 (fig.
2). No re ction was seen in pancreatic duct cells or
islets of Langerhans or in other human tissues studied
(liver, kidney, spieen, muscle, lymph node and thy-
roid). The specificity of the monoclonal antibody 2E1
was also investigated by TR-FIA (fig. 3). The anti-
body reacted with human, rat and porcine pancreatic
phospholipase A2 but not with bee venom phospho-
lipase A2 or phospholipase A2 purified from human
ascitic fluid.
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Fig. 1. SDS-PAGE electrophoresis (a) and immunoblotting (b)
pf an aqueous extraet of human pancreas and purified
pancreatic phospholipase A2.
a) SDS-PAGE was carried put äs described in the sec-
tion "Methods".
1. Molecular weight Standards (Mr 14400-94000).
2. Non-reduced pancreatic extraet.
3. Reduced pancreatie extraet.
4. Purified pancreatic phospholipase A2, non-reduced.
5. Purified pancreatic phospholipase A2, reduced.
b) Detection of pancreatic phospholipase A2 by immu-
noblotting performed äs described in the section "Meth^
ods".
1. Molecular weight Standards (Mr 14400-94000).
2. Purified pancreatic phospholipase A2.
3. Pancreatic extraet. Phospholipase A2 in lanes 2 and
3 was detected with the polyclonal sheep anti-phos-
phoiipase A2 antiserum.
4. Non-reduced pancreatic extraet.
5. Reduced pancreatic extraet. Phospholipase A2 in
lanes 4 and 5 was detected with the monoclonal anti^
phospholipase A2 antibody 2E1.
6. Purified pancreatic phospholipase A2, non-reduced.
7. Purified pancreatic phospholipase A2, reduced. Phos-
pholipase A2 in lanes 6 and 7 was detected with the
monoclonal antibody 2E1.
Fig. 2. Immunohistochemical localization of phosphoiipase A2
in human pancreas. A formaliti-fixed, paraffin-embed-
ded tissue section stained with affinity pxirified mono^
clonal antibody 2E1 (i.46 mg/1), avidin-biotin-cömplex
method (ABC). Acinar cells contain immunoreactive
material - Magnification 430x.
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Fig. 3. Specific binding of monoclonal anti-phospholipase A2
antibody 2E1 to pancreatic phospholipase A2 s deter-
mined by TR-FIA.
Microtitre plates were coated with l ng/well of phos-
pholipase A2 purified from
a) human pancreas
b) ral pancreas
c) porcine pancreas
d) bee venom and
e) human ascitic fluid.
After Saturation with a Saturation solution and incu-
bation with the monoclonal antibody 2E1, the immu-
noreaction was detected with an Eu-labelled rabbit anti-
mouse IgG second antibody. There is considerable
cross-reactivity between human, rat and porcine pan-
creatic phospholipase A2s, but none between human
pancreatic and ascitic fluid or bee venom phospholipase
A2s.
TR-FIA for human pancreatic phospholipase
A2
Standard curve, precision profile, detection limit and
assay r nge
The Standard curve for TR-FIA of human phospho-
lipase A2 and the precision profile calculated from 12
replicates (one strip) for each phospholipase A2 con-
centration are shown in figure 4. The coefficient of
intraassay Variation ranged from 2.8 to 9.9%. The
sensitiyity of the assay defined s equivalent to the
concentration cprresponding t the mean fluorescence
of zero Standard (12 replicates) plus twice the Standard
deviation was determined to be 0.28 μg/l. The r nge
of values that can be measured with this method is
0.28-324 μg/l.
Analytical recovery
Two different concentrations (20,150 μg/l) of human
phospholipase A2 Standards were added to five serum
samples with'starting phospholipase A2 values varying
from 4.11 to 28.49 μg/l. The percentage recovery of
phospholipase A2 was calculated s (amount found
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Fig. 4. Dose-response curve (o) and precision profile (o) for
the TR-FIA of human pancrealic phospholipase A2.
of added phospholipase A2/amount phospholipase A2
added ) χ 100. The analytical recoveries were 96.2%
and 123.1%, respectively, with an overall mean
109.6%.
Linearity
Four serum samples containing different concentra-
tions of phospholipase A2 (92.81, 18.07, 15.21 and
4.33 μg/l) were diluted serially with assay buffer and
analysed by TR-FIA. Excellent correlations
(r = 0.99, 1.00, 1.00 and 0.99, respectively) were
found in all four cases.
Reference interval
The mean concentration of phospholipase A2 in the
serum of 57 apparently healthy individuals (23
women, 34 men) was 5.8 μg/l (SD 1.4). Given the
parametric distribution of this analyte, the 95% ref-
erence interval was 3.1—9.0 μg/l.
Ihter-niethod comparison
For comparison with a TR-FIA method using poly-
clonal sheep anti-phospholipase A2 antibodies, the
concentration of phospholipase A2 in 67 sera (28
normal, 39 pancreatitis) was measured by both the
TR-FIA methods. The new assay was found to cor-
relate well with the comparison method. The results
were: y = 0.803x + 3.24; r = 0.95, n = 67 (fig. 6).
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Fig. 5. Distribution of values of pancreatic phospholipase A2
in sera of 23 healthy women and 34 men.
The mean age was 41 years (r nge 20 — 64). The mean
concentration of phospholipase A2 is 5.8 ±1.4
Discussion
Phospholipase A2 exists either s an extracellular se-
cretory enzyme or s an intracellular enzyme. The bee
and snake venom and pancreatic secretory phospho-
lipases A2 are typical extracellular enzymes. Intracell-
ular phospholipases A2 have been described in many
cell types, and they exist either in soluble form in the
cytosol, or they are membrane-bound in various sub-
cellular compartments (12 — 15). Membrane-associ-
ated and soluble phospholipases A2 differ in their
Substrate specificity (14) and hydrophobic properties
(15), and they may also be functionally distinct. Mem-
brane-bound phospholipases A2 are believed to par-
ticipate in the regulation of phospholipid metabolism
in biomembranes including the biosynthesis of eicos-
anoids and the acylation-deacylation cycle of phos-
pholipids (12).
Antibodies have been used to investigate immuno-
chemical and structural relationships between phos-
pholipases A2 from different sources. There are only
limited and somewhat contradictory data on the an-
tigenic relationship between intracellular and extra-
cellular phospholipases A2. A polyclonal antiserum
against human pancreatic phospholipase A2 did not
recognize snake venom phospholipases A2 (16) or
seminal fluid phospholipase A2 (17). kamoto et al.
(18) found immunological similarity between rat pan-
creatic phospholipase A2 and rat splenic microsomal
phospholipase A2. A monoclonal antibody against rat
liver mitochondrial phospholipase A2 reacted with rat
11
<M 200
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o
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Phospholipase A2
(polyclonal antibody) [pg/l]
400
Fig. 6. Correlation between two TR-FIA methods using either
sheep polyclonal or mouse monoclonal 2E1 anti-phos-
pholipase A2 antibody s the catching antibody.
Pancreatic phospholipase A2 concentrations were as-
sayed in serum samples of healthy individuals (n = 28)
and patients suffering from acute pancreatitis (n = 39).
The linear regression equation is y = 0.803x + 3.24;
r = 0.95, n = 67.
liver cytosol and rat platelet phospholipase A2 but did
not recognize rat or pig pancreatic phospholipase A2
or snake venom phospholipase A2 (19). Mollier et al.
(20) prepared a monoclonal antibody against mono-
meric phospholipase A2 from snake venoms, and
found that the antibody recognized phospholipase A2
from snake venoms but not from bee venom, porcine
pancreas, rat lymphocytes pr guinea pig alveolar mac-
rophages. Masliah et al. (21) demonstrated antigenic
similarity between an extracellular phospholipase A2
(Naja naja venom) and membrane-bound phospholi-
pase A2 from two different mammalian species and
cell types (guinea pig alveolar macrophages and rat
lymphocytes). In immunohistochemistry, the present
monoclonal antibody 2E1 was found to be specific to
pancreatic phospholipase A2. Iinmunoreactivity was
found in human pancreatic acinar eells but not in
other human tissues. We also investigated by TR-FIA
the cross-reactivity of the monoclonal antibody 2E1
with non-pancreatic phospholipases A2 (bee Venom
and human ascitic fluid phospholipase A2) and found
no cross-reactivity. However, we found definite cross-
reactivity with pancratic phospholipases A2 from
other mammalian species. The antibody 2E1 reacted
with rat and porcine pancreatic phospholipase A2, but
it showed the highest affinity for human pancratic
phospholipase A2. This finding confinns earlier ob-
servations that phospholipases A2 from human, rat
aiid porcine pancreas are closely related antigenically
(2,22).
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In the present study we developed a TR-FIA for the
measurement of human pancreatic phospholipase A2
based on the new monoclonal antibody 2E1, the latter
being used äs the catching antibody in a solid-phase
assay. The increased concentration of immunoreactive
pancreatic phospholipase A2 in serum is a specific and
sensitive marker of acinar cell injury that occurs e. g.
in acute pancreatitis. In our earlier study, we found
increased serum phospholipase A2 concentrations in-
variably at the early stages of both mild and severe
forms of acute pancratitis (5). The phospholipase A2
values were found to return to the reference interval
at a somewhat slower rate than corresponding amy-
lase activities in acute pancreatitis. The immunoreac-
tive phospholipase A2 may include the active enzyme,
the enzymatically inactive proenzyme and/or de-
graded fragments of the active enzyme that may be
catalytically active or inactive. Therefore immunoas-
says do not give any Information äs to the catalytic
activity of the phospholipase A2 enzyme molecule
being measured. Since the catalytic activity of phos-
pholipase A2 correlates with the severity of the disease
in acute pancratitis (6), it is advisible to measure both
the catalytic activity of phospholipase A2 and the
concentration of immunoreactive pancreatic phos-
pholipase A2 in the same serum samples in order to
specifically detect pancreatic acinar cell injury (by the
latter method) and to assess the severity of the disease
process (by the former method). There is an ample
selection of methods available for the determination
of phospholipase A2 catalytic activity (23).
The previously reported radioimmunoassays and the
TR-FIA for measuring the concentration of human
immunoreactive pancreatic phospholipase A2 employ
polyclonal antibodies raised in rabbits (1—3, 5). The
use of a monoclonal instead of a polyclonal antibody,
however, would offer the advantage of unlimited sup-
ply, constant and predictable quality, and high spec-
ificity. Recently another RIA-method for the deter-
mination of pancreatic phospholipase A2 employing
a monoclonal antibody was described (4).
The mean (± SD) phospholipase A2 value, 5.8 ±1.4
g/l, measured in sera of healthy individuals by the
present TR-FIA agrees well with the phospholipase
A2 concentrations found by different immunoassays
(RIA, TR-FIA): 6.5 ± 2.0 ^ (serum, 1), 5.1 + 1.7
§/1 (serum, 2), 4.3 ± 1.3 §/1 (plasma, 3), 2.4 ± 0.69
g/l (serum, 4) and 5.5 ±1.9 g/l (serum, 5). A good
correlation between the present method and a TR-
FIA described earlier by us (1) was found (data not
shown). Likewise, measurements by the present
method correlated very well (r = 0.95) with those
obtained from the same normal and pathological
serum samples by a method using a polyclonal sheep
antibody both äs the catching and detecting antibody
in a solid-phase TR-FIA (present study).
In summary, we describe a new monoclonal antibody
2E1 to human pancreatic secretory phospholipase A2
showing no cross-reactivity with other human tissues
or ascitic phospholipase A2. A specific TR-FIA
method was developed to measure pancreatic phos-
pholipase A2 in serum samples.
Acknowledgement
The authors thank Ms Sinikka Kollanus and Ms Tinda Manninen
for technical assistance, Mr Jaakko Lüppo for photography, Dr
Juha Grönroos for serum samples and Dr Vesa Kleimola for
fruitful discussions.
References
1. Eskola, J. U., Nevalainen, T. J. & Lövgren, T. N.-E. (1983)
Time-resolved fluoroimmunoassay of human pancreatic
phospholipase A2. Clin. Chem. 29, 1777-1780.
2. Nishijima, J., Okanaoto, M., Ogawa, M., Kasaki, G. &
Yamano, T. (1983) Purification and characterization of
human pancreatic phospholipase A2 and development of a
radioimmunoassäy. J. Biochem, 94, 137—147.
3. Sternby, B. & Äerström, B. (1984) Immunoreactive pan-
creatic colipase, lipase and phospholipase A2 in human
plasma and urine from healthy individuals. Biochim. Bio-
phys. Acta 789, 164-169.
4. Oka, Y., Ogawa, M., Matsuda, Y, Murata, A., Nishijima,
J., Miyauchi, K., Udä, K., Yasuda, T. & Mori, T. (1990)
Serum immunoreactive pancreatic phospholipase A2 in pa-
tients with variöus m^lignant tumours. Enzyme 43, 80—88.
5. Nevalainen, T. J., Eskola, J. U, Aho, A. J., Havia, V. T.,
Lövgren, T. N.-E. & Näntö, V. '(1985) Immunoreactive
phospholipase A2 in serum in acute pancreatitis and pan-
creatic cancer. Clin. Chem. 31, 1116-1120«.
6. Büchler, M., Malfertheiner, R, Schädlich, H., Nevalainen,
T., Mavromatis, T. & Beger, H. G. (1989) Prognoslic value
of serum phospholipase A2 in acute pancreatitis. Klin.
Wochenschr. 67, 186-189:
7. Kortesuo, P. T. & Nevalainen, T. J. (1991) Phospholipase
A2 in human ascitic fluid: purification, characterization and
immunochemical detection. Biochem. J. 278, 263 — 267.
8. Eskola, J. U, Nevalainen, T. J. & Aho, H. J. (1983) Puri-
fication and characterization of human pancreatic phos-
pholipase A2. Clin. Chem. 29, 1772-1776.
9. Galfre, G. & Milstein, C. (1981) Preparation of monoclonal
antibodies: strategies and procedures. Methods Enzymol.
73, 3-46.
10. Hemmilä, L, Dakubu, S., Mukkala, V-M., Siitari, H. &
Lövgren, T. (1984) Europium äs a label in time-resolved
immunofluorometric assays. Anal. Biochem. 137, 335—
343.
11. International Federation of Clinical Chemistry (1987) Ap-
proved recommendation (1987) on the theory of reference
values. Part 5r Statistical treatment of collected reference
values. Determinations of reference limits. J. Clin. Chem.
Clin. Biochem. 25, 645—656.
12. van den Bosch, H. (1980) Intracellular phospholipases A.
Biochim. Biophys. Acta 604, 191-246.
13. van den Bosch, H. (1982) Phospholipases. In: New Com-
prehensive Biochemistry, vol. 4 (Havvthorne, J. N. & Ansell,
G. B., eds), pp. 313 — 357 Eisevier, Amsterdam.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 12
826 Santavuori et al.: Monoclonal anti-pancreatic phospholipase A2 antibody
14. Gonzaiez-Buritica, H., Smith, D. M. & Turner, R. A. (1989)
Characterization of soluble and cell associated phospholi-
pase A2 from rheumatoid synovial fluid. Ann. Rheum. Dis.
48, 557-564.
15. Ono, T., Tojo, H., Kuramitsu, S., Kagaraiyama, H. Oka-
moto, M. (1988) Purification and characterization of a
membrane-associated phospholipase A2 from rat spieen. J.
Biol. Chem. 263, 5732-5738.
16. Meijer, H., Meddens, M. J. M., Dijkman, R., Slotboom,
A. J. & de Haas, G. H. (1978) Immunological studies on
pancreatic phospholipase A2. J- Biol. Chem. 2S3, 8564—
8569.
17. Wurl, M. & Kunze, H. (1985) Purification and properties
of phospholipase A2 from human seminal plasma. Biochim.
Biophys. Acta 834, 411-418.
18. Okamoto, M., Onto, T., Tojo, H. & Yamano, T. (1985)
Immunochemical relatedness between secretory phospho-
lipase A2 and intracellular phospholipase A2. Biochim. Bio-
phys. Res. Commun. 128, 788-794.
19. de Jong, J. G. N., Arnesz, H., Aarsman, A. J., Lenting, H.
B. M. & van den Bosch, H. (1987) Monoclonal ä^tibodies
against an intracellular phospholipase A2 from rat liver and
their cross-reactivity with other phospholipase A2. Eur. J.
Biochem. 164, 129-135.
20. Mollier, R, Chwetzoff, S. & Menez, A. A. (1990) A möno-
clonal antibody recognizing conserved epitope in a groüp
of phospholipase A2. Mol. Immunol. 27, 7—15.
21. Masliah, J., Kadir, C., Pepin, D.vilybkine, T., Etienne, J.,
Chambaz, J. & Bereziat, G. (1987) Antigenic relatedness
between phospholipase A2 from Naja naja venom and ff öm
mammalian cells. FEBS Lett. 222, 11 — 16.
22. Ono, T., Tojo, H., Inoue, K., Kagamiyama, H., Yamano9
T. & Okamoto, M. (1984) JRat pancreatic phospholipase
A2: purification, characterization, and N-terminal amino
acid sequence. J. Biochem. 96, 785 — 792.
23. Nevalainen, T. J. (1988) Phospholipase A2 in acute pan-
creatitis. Scand. J. Gastroenterol. 23, 897—904.
Dr. Timo Nevalainen
Department of Pathology
Kiinamyliynkatu 10
SF-20520 Turku
y Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 12
